Aquestive Therapeutics
AQST
3.46
-0.25
-6.61%
Aquestive Therapeutics
US · AQST
#3650 by market cap
Listed 2018
3.46
-0.25
-6.61%
Periodic snapshot; not a real-time feed.
· 2026-11-20 20:02
✦ Quant Ownership Signal how this is computed
Distributing
- The number of reporting institutions decreased by 1 in the most recent period (2026/Q3).
- Total institutional ownership fell 0.6 percentage points.
Ownership vs. money flow
AlignedInstitutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Institutional ownership
- Held by institutions
- 57.49% -0.56pp
- Institutions
- 208 -1
- As of
- 2026/Q3 vs. prior period
Holder types
Mutual Fund34.08%
Hedge Fund12.75%
Public Company4.30%
Individual/Insider4.04%
VC/PE Fund2.74%
Private Company2.28%
Insurance Company0.79%
Family Office/Trust0.34%
Government Pension Fund0.21%
Other38.47%
Top holders as of 2026-09-30
BlackRock
6.53% · 8.21M sh
Bratton Capital Management, L.P.
7.82% · 9.81M sh
Thru Line L.P.
6.27% · 7.88M sh
RTW Investments, LP
5.91% · 7.43M sh
Vanguard Capital Management, LLC
3.81% · 4.78M sh
State Street Global Advisors
2.77% · 3.48M sh
Federated Hermes, Inc.
2.54% · 3.20M sh
Geode Capital Management, LLC
2.30% · 2.90M sh
Samsara BioCapital LLC
1.99% · 2.50M sh
Bank of America Corporation
1.33% · 1.67M sh
Edward Bass
1.20% · 1.51M sh
Sio Capital Management, LLC
1.18% · 1.49M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 22 buys · 26 sells
| Name | Role | Stake |
|---|---|---|
| Daniel Barber | Chief Executive Officer | 0.50% |
| Stephen Wargacki | Former Chief Science Officer | 0.27% |
| Peter Boyd | Senior Vice President of Information Technology & Chief People Officer | 0.23% |
| A. Toth | Senior Vice President | 0.23% |
| Carl Kraus | Former Chief Medical Officer | 0.22% |
| Melina Cioffi | Senior Vice President of Regulatory Affairs | 0.22% |
| Douglas Bratton | Former Independent Director | 0.20% |
| Sherry Korczynski | Chief Commercial Officer | 0.19% |
| Lori Braender | Corporate Secretary | 0.18% |
| Cassie Jung | Chief Operating Officer | 0.17% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-11-09 | Richard John Daly | Independent Director | Open Market Acquisition | +28,025 | $3.53–3.55 |
| 2026-11-09 | Matthew Davis | Chief Development Officer | Sale to Issuer | -5,303 | $3.52 |
| 2026-11-05 | Richard John Daly | Independent Director | Other Derivative Acquisition | +57,000 | $3.61 |
| 2026-10-20 | John Cochran | Independent Vice Chairperson | Other Acquisition | +62,229 | -- |
| 2026-10-14 | Richard John Daly | Independent Director | Initial Statement of Beneficial | 0 | -- |
| 2026-10-14 | Daniel Barber | Chief Executive Officer | Open Market Disposition | -25,000 | $4.22 |
| 2026-09-14 | Daniel Barber | Chief Executive Officer | Open Market Disposition | -25,000 | $4.82 |
| 2026-09-08 | Peter Boyd | Senior Vice President of Information Technology & Chief People Officer | Derivative Exercise and Retained | +2,293 | $0.96 |
| 2026-09-08 | Sherry Korczynski | Chief Commercial Officer | Derivative Exercise and Sale | -8,750 | $2.65–5.22 |
| 2026-09-07 | Daniel Barber | Chief Executive Officer | Derivative Exercise and Retained | +91,743 | $0.96 |
| 2026-09-02 | Cassie Jung | Chief Operating Officer | Derivative Exercise and Retained | +4,587 | $0.96 |
| 2026-08-16 | Daniel Barber | Chief Executive Officer | Open Market Disposition | -25,000 | $4.29 |
| 2026-08-13 | Sherry Korczynski | Chief Commercial Officer | Sale to Issuer | -2,714 | $4.25 |
| 2026-07-15 | Daniel Barber | Chief Executive Officer | Open Market Disposition | -25,000 | $4.00–4.03 |
| 2026-07-14 | Daniel Barber | Chief Executive Officer | Intent to Sell (Form 144) | -25,000 | $4.04 |
| 2026-06-22 | Julie Krop | Independent Director | Derivative Exercise and Sale | -25,000 | $0.71–5.02 |
| 2026-06-14 | Daniel Barber | Chief Executive Officer | Open Market Disposition | -25,000 | $4.16 |
| 2026-06-09 | Timothy Morris | Independent Director | Other Derivative Acquisition | +50,500 | $3.99 |
| 2026-06-09 | Gregory Brown | Independent Chairperson | Other Derivative Acquisition | +50,500 | $3.99 |
| 2026-06-09 | Julie Krop | Independent Director | Other Derivative Acquisition | +50,500 | $3.99 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-11-20 20:02:37 · For reference only, not investment advice and not tailored to your situation.
Aquestive Therapeutics discussion 0 comments